What is Tasly Pharmaceutical Group Co., Ltd's (600535.SS) StockRank?

MoatMap's StockRank for Tasly Pharmaceutical Group Co., Ltd (600535.SS) is 86/100, with a Strong Buy signal. This is a composite score combining Quality (67), Value (54), and Momentum (52) factor ranks across MoatMap's 19,000+ stock universe.

Does Tasly Pharmaceutical Group Co., Ltd have an economic moat?

Tasly Pharmaceutical Group Co., Ltd (600535.SS) has a Quality factor score of 67/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Tasly Pharmaceutical Group Co., Ltd a buy, hold, or sell?

MoatMap's current signal for Tasly Pharmaceutical Group Co., Ltd (600535.SS) is Strong Buy, based on a StockRank of 86/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Tasly Pharmaceutical Group Co., Ltd in?

Tasly Pharmaceutical Group Co., Ltd (600535.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600535.SS

STRONG BUYREMOVE

Tasly Pharmaceutical Group Co., Ltd · Healthcare · China · $3.1B · Avg Vol: $19M/d

StockRank

P/E (TTM)

18.6x

ROE

8.7%

D/E

0.7x

Dividend %

2.2%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Tasly Pharmaceutical focuses on Traditional Chinese Medicine, which lacks the global scalability, clear regulatory moats, and high-conviction growth drivers we require.

COMPANY DESCRIPTION

Tasly Pharmaceutical Group Co., Ltd. develops and manufactures modern Traditional Chinese Medicine (TCM), chemical drugs, and biologics, with a focus on cardiovascular therapies. The company is a pioneer in modernizing TCM through standardized, scientific clinical trials, holding a dominant position with its flagship Compound Danshen Dripping Pills. It is a research-driven, vertically integrated pharmaceutical leader bridging traditional Chinese therapies with global medical standards.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	1.3B	1.3B	1.3B	1.2B	-1.6%
EPS	-0.03	0.11	0.09	0.11	1.4%
Shares	1.5B	1.5B	1.5B	1.5B	-0.4%
Debt	320M	405M	245M	213M	-12.8%
Equity	1.8B	1.8B	1.8B	1.8B	-0.0%
Op CF	337M	381M	298M	211M	-14.5%
Inv CF	-187M	-312M	-139M	-66M	—
Fin CF	-35M	-177M	-363M	-55M	—

PRICE (1M)-6.0%

SMA 50SMA 200

$2.10

RSI (14)

54.0

52W High

$2.56

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

10.6%74.8

ROE

8.7%68.7

GP/Assets

37.1%76.1

Op. Margin

12.8%71.0

FCF/Assets

8.5%82.7

Piotroski

—83.5

Int. Cover

42.4x81.7

D/E Ratio

0.69x23.7

Current Ratio

3.71x61.0

Value

P/E (TTM)

18.6x61.2

EV/EBITDA

15.3x27.2

P/FCF

110.1x64.8

P/B

1.7x61.6

P/S

2.6x60.6

Div Yield

2.2%54.1

Momentum

52W High %

82%77.6

RS 6M

-14%63.0

SMA 50/200

0.96x50.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+14%30.0

Q Growth

-34%16.4

FUNDAMENTALS

Market Cap

$3.1B

P/E (Forward)

16.3x

Gross Margin

67.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600535.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600535.SS	Tasly Pharmaceutical Group Co., Ltd(you)	$3.1B	86	STRONG BUY
2096.HK	Simcere Pharmaceutical Group Limited	$3.3B	91	STRONG BUY
600062.SS	China Resources Double-Crane Pharmaceutical Co.,Ltd.	$2.6B	88	STRONG BUY
000739.SZ	Apeloa Pharmaceutical Co.,Ltd	$2.8B	91	STRONG BUY
002262.SZ	Jiangsu Nhwa Pharmaceutical Co., LTD	$3.0B	79	BUY
600329.SS	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited	$4.6B	86	STRONG BUY
600867.SS	Tonghua Dongbao Pharmaceutical Co., Ltd.	$2.4B	90	STRONG BUY
600380.SS	Joincare Pharmaceutical Group Industry Co.,Ltd.	$2.8B	93	STRONG BUY
600420.SS	Shanghai Shyndec Pharmaceutical Co., Ltd.	$1.8B	85	STRONG BUY
002773.SZ	Chengdu Kanghong Pharmaceutical Group Co., Ltd	$2.9B	75	BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Tasly Pharmaceutical Group Co., Ltd (600535.SS) — Stock Score Summary

Tasly Pharmaceutical Group Co., Ltd (600535.SS) has a MoatMap StockRank of 86/100 based on Quality (67/100), Value (54/100), and Momentum (52/100) factor scores. The current signal is STRONG BUY. Tasly Pharmaceutical focuses on Traditional Chinese Medicine, which lacks the global scalability, clear regulatory moats, and high-conviction growth drivers we require.

Key Financial Metrics

Price	$2.10
Market Cap	$3.1B
P/E (TTM)	18.56
P/E (Forward)	16.27
Price/Book	1.69
Return on Equity	8.7%
Return on Invested Capital	10.6%
Debt/Equity	68.80
Gross Margin	67.9%
Operating Margin	12.8%
Revenue Growth	-13.5%
Dividend Yield	2.2%
Free Cash Flow	$28M

Tasly Pharmaceutical Group Co., Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Tasly Pharmaceutical Group Co., Ltd’s (600535.SS) StockRank?: MoatMap’s StockRank for Tasly Pharmaceutical Group Co., Ltd (600535.SS) is 86/100, with a Strong Buy signal. It is a composite of Quality (67), Value (54), and Momentum (52) factor ranks across MoatMap’s 19,000+ stock universe.
Does Tasly Pharmaceutical Group Co., Ltd have an economic moat?: Tasly Pharmaceutical Group Co., Ltd (600535.SS) has a Quality factor score of 67/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Tasly Pharmaceutical Group Co., Ltd a buy, hold, or sell?: MoatMap’s current signal for Tasly Pharmaceutical Group Co., Ltd (600535.SS) is Strong Buy, based on a StockRank of 86/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Tasly Pharmaceutical Group Co., Ltd in?: Tasly Pharmaceutical Group Co., Ltd (600535.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).